Daniil Gataulin
Stock Analyst at Chardan Capital
(0)
# 4414
Out of 5,329 analysts
87
Total ratings
31.82%
Success rate
-13.97%
Average return
Main Sectors:
Top Industries:
| Name | Action | PT | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
UBX Unity Biotechnology | Maintains: Buy | 4 4 | 1.1 | 263.64% | 4 | Apr 23, 2025 | |
TRML Tourmaline Bio | Initiates Coverage On: Buy | 70 | 17.89 | 291.28% | 1 | Apr 23, 2025 | |
ADVM Adverum Biotechnolog... | Maintains: Buy | 40 33 | 3.33 | 890.99% | 6 | Apr 17, 2025 | |
OCS Oculis Holding | Maintains: Buy | 28 28 | 17.53 | 59.73% | 6 | Apr 17, 2025 | |
FBRX Forte Biosciences | Maintains: Buy | 64 61 | 6.95 | 777.7% | 4 | Apr 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Strong Buy | 27 38 | 14.98 | 153.67% | 1 | Apr 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 6 6 | 0.85 | 605.88% | 4 | Mar 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 11 8 | 0.45 | 1677.78% | 6 | Mar 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 52 52 | 9.87 | 426.85% | 10 | Mar 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 14 14 | 10.6 | 32.08% | 5 | Mar 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 33 33 | 7.12 | 363.48% | 10 | Mar 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Strong Buy | 6 7 | 0.74 | 845.95% | 10 | Mar 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 36 36 | 7.27 | 395.19% | 3 | Feb 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 3 3 | 1.58 | 89.87% | 8 | Feb 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 220 220 | 2.35 | 9261.7% | 1 | Mar 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | n/a | n/a | n/a | 2 | Jul 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | n/a | n/a | n/a | 2 | Feb 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 22 13 | n/a | n/a | 2 | Nov 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 5 3 | n/a | n/a | 2 | Sep 28, 2022 |